<DOC>
	<DOC>NCT02892149</DOC>
	<brief_summary>A multicenter, randomized, open-label, active-controlled Phase 3 study for the maintenance treatment of anemia in subjects with DD-CKD</brief_summary>
	<brief_title>Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Dialysis-dependent Chronic Kidney Disease (DD-CKD)</brief_title>
	<detailed_description>This is a multicenter, randomized, open-label, active-controlled Phase 3 study of the efficacy and safety of vadadustat versus darbepoetin alfa for the maintenance treatment of anemia in subjects with DD-CKD</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>â‰¥18 years of age Receiving chronic maintenance dialysis (either peritoneal or hemodialysis) for endstage kidney disease for at least 12 weeks prior to Screening Currently maintained on ESA therapy, with the last dose received within 8 weeks prior to Screening Mean Screening HGB between 8.0 and 11.0 g/dL (inclusive) in the US and between 9.0 and 12.0 g/dL (inclusive) outside of the US Uncontrolled hypertension Severe heart failure at Screening (New York Heart Association Class IV) Acute coronary syndrome (hospitalization for unstable angina or myocardial infarction), surgical or percutaneous intervention for coronary, cerebrovascular or peripheral artery disease (aortic or lower extremity), surgical or percutaneous valvular replacement or repair, sustained ventricular tachycardia, hospitalization for HF, or stroke within 12 weeks prior to or during Screening Hypersensitivity to vadadustat, darbepoetin alfa, or any of their excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>AKB-6548</keyword>
	<keyword>Chronic kidney disease</keyword>
	<keyword>anemia</keyword>
	<keyword>CKD</keyword>
	<keyword>chronic renal insufficiency</keyword>
	<keyword>renal impairment</keyword>
	<keyword>erythropoietin</keyword>
	<keyword>kidney</keyword>
	<keyword>renal</keyword>
	<keyword>oral anemia treatment</keyword>
	<keyword>hemoglobin</keyword>
	<keyword>hypoxia-inducible factor</keyword>
	<keyword>HIF</keyword>
	<keyword>hypoxia-inducible factor prolyl-hydroxylase inhibitor</keyword>
	<keyword>HIF-PHI</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
	<keyword>Phase 3</keyword>
	<keyword>cardiovascular</keyword>
	<keyword>DD-CKD</keyword>
</DOC>